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Vagus nerve stimulation (VNS) is a neurophysiological treatment for patients with medically or surgically refractory epilepsy.
Since the first human implant in 1989, more than 10 000 patients have been treated with VNS. Two randomized controlled
studies have shown a statistically significant decrease in seizure frequency during a 12-week treatment period versus a baseline
period when ‘high stimulation’ mode was compared with ‘low stimulation’ mode. The efficacy appears to increase over time.
In general, one third of the patients show a >50% reduction of seizure frequency; one third show a 30–50% seizure reduction,
and one third of patients show no response. Few patients become seizure-free. Side effects during stimulation are mainly voice
alteration, coughing, throat paraesthesia and discomfort. When studied on a long-term basis, VNS is an efficacious, safe and
cost-effective treatment not only in adults but also in children and the elderly. The precise mechanism of action remains to
be elucidated. In recent years much progress has been made through neurophysiological, neuroanatomical, neurochemical and
cerebral blood flow studies in animals and patients treated with VNS. Further elucidation of the mechanism of action of VNS
may increase its clinical efficacy and our general understanding of some physiopathological aspects of epilepsy. Finally, VNS
may become an alternative treatment for other conditions such as depression and pain.
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INTRODUCTION
Epilepsy is the second most common chronic neuro-
logical disorder after stroke affecting approximately
0.5–2% of the population1. Seventy percent of
patients can be successfully treated with one or
more antiepileptic drugs (AEDs). Despite adequate
antiepileptic treatment 30% of patients continue to
have seizures or experience unacceptable pharmaco-
logical side effects2. For these patients with ‘medically
refractory’ epilepsy, epilepsy surgery is a therapeutic
alternative. Resective surgery is a curative therapy
when the epileptogenic zone can be identified and
renders 60–90% of patients seizure free3. Pre-surgical
evaluation requires a thorough patient selection and
in a substantial number of patients the epileptogenic
zone cannot be identified or is located in a functional
brain area. Unsuitable candidates for resective surgery
have few options left. Administration of a new AED
will lead to seizure freedom in a maximum of 7%
of patients4. Electrical stimulation of the vagus nerve
is an efficacious neurophysiological treatment for
patients with refractory epilepsy who are unsuitable
candidates for curative resective surgery or who have
experienced insufficient benefit from such a treatment.
HISTORY
The first vagus nerve stimulator was implanted in
humans in 1988. However, the historical basis of
peripheral stimulation for treating seizures dates back
to centuries ago. In the sixteenth and seventeenth
century physicians described the use of a ligature
around the limb in which a seizure commences to
arrest its progress. This method is due to Pelops for
whom this observation was proof that epileptic fits
originated from the limb itself. This hypothesis was
reviewed in the beginning of the nineteenth century
when Odier5 and also Brown-Se´quard showed that
ligatures are equally efficacious in arresting seizures
caused by organic brain disease e.g. a brain tumour.
At the end of this century Gowers attributed these
findings to a raised resistance in the sensory and motor
nerve cells in the brain that correspond with the limb
involved. This would in turn arrest the spread of the
discharge. Gowers6 also reported several other ways
by which sensory stimulation could prevent seizures
from spreading e.g. pinching of the skin and inhalation
of ammonia. Almost a hundred years later Rajna and
Lona7 demonstrated that afferent sensory stimuli can
abort epileptic paroxysms in humans.
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ANATOMICAL BASIS
The left vagus nerve is a mixed cranial nerve that
consists of ∼80% afferent fibres originating from the
heart, aorta, lungs and gastrointestinal tract and of
∼20% efferent fibres that provide parasympathetic
innervation of these structures and also innervate
the voluntary striated muscles of the larynx and the
pharynx8. Somata of the efferent fibres are located
in the dorsal motor nucleus and nucleus ambiguus,
respectively. Afferent fibres have their origin in the
nodose ganglion and primarily project to the nucleus
of the solitary tract. The nucleus of the solitary
tract (NTS) has widespread projections to numerous
areas in the forebrain as well as the brainstem
including important areas for epileptogenesis such as
the amygdala and the thalamus. There are direct neural
projections into the raphe nucleus, which is the major
source of serotonergic neurons and indirect projec-
tions to the locus coeruleus and A5 nuclei that contain
noradrenergic neurons. Finally, there are numerous
diffuse cortical connections. The diffuse pathways of
the vagus nerve mediate important visceral reflexes
such as coughing, vomiting, swallowing, control of
blood pressure and heart rate. Heart rate is mostly
influenced by the right vagus nerve that has dense
projections primarily to the atria of the heart9.
MECHANISMS OF ACTION
Early animal experiments investigated the effect
of stimulation of the cervical vagus nerve on the
EEG. Depending on the level of anaesthesia and
the stimulus parameters used, vagus nerve stimula-
tion (VNS) can induce EEG synchronization, EEG
desynchronization, rapid eye movement and sleep
or slow wave sleep10, 11. Desynchronization results
from high-intensity and high-frequency (>70 Hz)
stimuli activating unmyelinated C-fibres. Lower in-
tensity, high-frequency (>70 Hz) stimulation induces
synchronization due to activation of myelinated A-
and B-fibres. Desynchronization may also be caused
by high-intensity, slower stimulation in the range
of 20–50 Hz. VNS blocks interictal spike activity
induced by strychnine applied to the cortex of the
cat10. Zabara12. found that generalized seizures in
dogs induced by pentylenetetrazol and strychnine
were inhibited by VNS and he made an estimation
about optimal stimulation parameters. These were
found to be 20–30 Hz frequency, 3.5–7 mA output
current and 0.2 milliseconds stimulus duration. Wood-
bury and Woodbury13 established the anticonvulsant
efficacy of VNS using frequencies above 4 Hz in
rats after induction of seizures with pentylenetetra-
zol, mercaptoproprionate and maximal electroshock.
Chronic VNS also reduced the frequency of recurrent
spontaneous seizures in monkeys with alumina gel
foci14. Using c-fos, a nuclear protein that is expressed
in neurons as a result of high neuronal activity,
Naritoku et al.15 were the first to identify some
key structures in the neuronal network between
brainstem and forebrain that are activated during VNS.
VNS induced severe staining in limbic structures
such as the amygdala, a highly epileptogenic region
that plays a role in the generalization of seizures.
The habenula and posteromedian nucleus of the
thalamus, structures implicated in seizure regulation,
also showed intense c-fos immunoreactivity. Support
for a role of monoamines in the mechanism of
action of VNS was found through VNS induced
c-fos activation in the locus coeruleus and A5 nuclei
of the brainstem. Takaya et al.16 showed that the
antiseizure effect of VNS outlasts the duration of the
stimulation train and repetition of stimuli increases
VNS efficacy. Krahl et al.17 performed bilateral
lesioning of the locus coeruleus in rats that was
shown to block the anticonvulsant effects of VNS
by preventing VNS-induced norepinephrine release.
Walker et al.18 showed that an increase in γ -
aminobutyric acid (GABA) or a decrease of glutamate
transmission in the rat NTS reduces the severity of
limbic seizures. VNS may therefore exert its anti-
seizure effect by inhibition of ascending outputs from
the NTS that project via various anatomic connections
to the forebrain. Krahl et al.19 found strong evidence
that vagal C-fibres are not responsible nor necessary
for the seizure-suppressing effect of VNS. According
to their experiments in awake and freely moving
rats, activation of myelinated A- and B-fibres were
shown to be responsible for seizure suppression. The
efficacy and mode of action of VNS has mainly
been studied in acute animal models for epilepsy.
Fernandez-Guardiola et al.20 performed VNS studies
in electrically kindled cats, a model for chronic
epilepsy. Their results showed that VNS delays the
development of seizures induced by electrical kindling
in the amygdala suggesting a possible preventative
effect of VNS on epileptogenesis. These results were
confirmed by Naritoku et al.21 who evaluated the
effects of VNS in electrically kindled rats. To date
no studies in animal models with spontaneous primary
generalized epilepsy have been published. Preliminary
results from our group22 at Ghent University Hospital
who studied VNS in genetic absence epilepsy rats
from Strasbourg (GAERS), suggest that short-term
VNS does not reduce frequency or duration of absence
seizures.
The first experimental work in humans aimed to
reproduce the EEG findings from animal experiments.
VNS-induced suppression of interictal epileptic ac-
tivity recorded by scalp EEG could not be demon-
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strated23. In one patient ictal EEG activity was
abruptly terminated by acute VNS. In another patient
bilateral rhythmical delta activity during an aura
was also interrupted by acute VNS. In three other
patients acute VNS, delivered well into an ongoing
seizure, did not have any influence on the EEG
or behavioural symptoms. Using fast Fourier EEG
analysis, no changes of normal background EEG
during wakefulness, sleep or anaesthesia were found.
Acute or chronic VNS does not have any influence
on the different diagnostic EPs (visual, auditory
brainstem, auditory 40 Hz and long-latency cogni-
tive EPs)24. Naritoku et al.25 performed brainstem
auditory evoked potentials (BAEP) and somatosensory
evoked potentials (SSEP) to determine if chronic VNS
results in electrophysiologically measurable changes.
There was no influence on BAEP. There was a
significant increase in the interval between cervi-
comedullary and thalamocortical potentials (N13–N20
interval) when three VNS patients were compared
after 1 month of stimulation with three normal
individuals and with baseline findings before VNS.
Findings by Naritoku et al.26 were confirmed in
another study that showed delays in latencies of
evoked responses induced by direct oesophagal
stimulation in VNS treated patients. Neurochemical
studies quantified amino-acid and neurotransmitter
metabolite concentrations in CSF samples before and
after VNS in order to clarify the hypothesis that VNS
might act through the release of neurotransmitters and
other compounds at the projection site of the vagus
nerve27, 28. The first study revealed selective increases
in 5-hydroxyindoleacetic acid and homovanillic acid,
metabolites of serotonin and dopamine, respectively.
Also a significant decrease of the levels of aspartate
was found correlating with better seizure control.
The second study revealed increased GABA and
ethanolamine levels, mainly in responders. While
serotoninergic as well as dopaminergic systems have
been found to have anticonvulsant effects in animal
and human studies of various types of epilepsy,
it remains to be clarified whether these findings
are epiphenomena or findings directly related to
VNS. Finally the effect of VNS on human CNS
structures has been studied through cerebral blood
flow (CBF) studies. Various changes in supratentorial
and cerebellar CBF caused by acute and chronic
VNS have been reported. Garnett et al.29 found
ipsilateral activation in the thalamus and cingulate
gyrus in five patients. A study by Ko et al.30 in three
patients reported increased CBF in the left posterior
cerebellum and putamen and in the right medial
temporal gyrus and thalamus. The main conclusion
was that VNS induces measurable CBF changes in
anatomic structures that are part of the diffuse vagus
nerve pathways. Occurrence of (subclinical) seizures
during scanning and previous resective surgery in
these early studies may have influenced the results and
may account for discrepancies in the reported findings.
Ko31 extended his study and finally examined nine
individuals in whom changes in CBF were correlated
with seizure control. A reduction in seizure frequency
best correlated with decreased CBF in the right
fusiform gyrus. VNS was also shown to exert an
effect on CBF longer than the duration of the
stimulation train. The first PET study of acute VNS
showed diffuse CBF changes32. Acute CBF changes
were correlated with seizure control after 3 months
of VNS (three responders vs. 11 non-responders).
Bilateral thalamic hyperperfusion correlated most
significantly with a decrease in seizure frequency
suggesting that alterations in thalamic activity may
contribute to antiseizure effects of VNS. Repeated
PET studies in the same patients after 3 months
showed that decreased CBF in bilateral hippocampi,
amygdala and cingulate gyrus and increased bilateral
insular CBF that was found during acute VNS
was no longer present33. Our group34 performed
an acute 99mTechnetium SPECT activation study in
11 patients, receiving an initial stimulation train
(output: 0.25–0.50 mA, frequency: 30 Hz, pulse width:
500 µseconds, on time: 30 seconds), that revealed
ipsilateral thalamic hypoperfusion as the most signifi-
cant finding. No significant CBF increases were found.
In a follow-up study 23 patients underwent an acute
activation paradigm and a subgroup of 10 patients also
underwent a SPECT activation study after 6 months
of chronic VNS. CBF changes were compared with
clinical outcome35. Chronic VNS (as compared to
baseline CBF before stimulation) resulted in decreased
CBF in bilateral thalami and the left caudate head.
During the activation paradigm in a chronic situation
in which the generator was activated with an additional
0.25 mA during 30 seconds a significant left thalamic
activation was found. An acute PET study by the same
group during the first stimulation train (0.25–0.50 mA,
30 Hz, 500 µseconds, 30 seconds) in six patients36
showed significantly increased CBF in the right
thalamus and somatosensory cortex and left inferior
cerebellum. Significantly decreased CBF was found
in the left fusiform gyrus and in bilateral dorsolateral
parietal cortex. In a recent study with eight patients
Ring et al.37 found a bilateral thalamic perfusion
decrease after chronic intermittent stimulation.
NCP DEVICE AND SURGICAL PROCEDURE38
In man, stimulation of the vagus nerve is facilitated
by implantation of the Neurocybernetic Prosthesis
(NCPTM) System (Cyberonics Inc, Houston, Texas),
which comprises a pulse generator and bipolar helical
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lead with an integral tether. The surgical procedure re-
quires two incisions. The first, for the pulse generator,
is approximately 8 cm wide and 2 cm beneath the
left clavicle and the other approximately 10 cm wide
at the anterior border of the left sternocleidomastoid
muscle. The operative procedure is usually performed
under general anaesthesia with the patient remaining
in the hospital overnight. Some centres are, however,
turning to regional anaesthesia and day care surgery.
Programming is facilitated with a radio frequency
telemetry wand connected to an IBM compatible
computer loaded with the NCPTM software. The
programmable parameters, together with their ranges,
are shown in Table 1. Stimulation can be initiated
immediately after the surgical procedure when the
patient is still under anaesthesia or after the patient has
fully recovered from the surgery, typically 1–2 weeks
later. In either case, the output current is subsequently
increased according to patient tolerance. The patient
may also be provided with a magnet. The magnet
allows additional stimulation to be commanded by
the patient or carer in case of an aura or a seizure.
Additional stimulation is facilitated by passing the
magnet over the pulse generator for 1–2 seconds. The
magnet may also be used to inhibit stimulation by
keeping it over the generator. The system can be safely
removed by explanting the generator and lead39. Since
the first human implant an estimated 10 000 patients
have been treated with VNS.
CLINICAL TRIALS
Clinical efficacy and side effects
Five (E01–E05) acute-phase clinical studies involving
the NCPTM system have been conducted in a total
population of 454 patients. The purpose of the
studies was to determine whether adjunctive use of
electrical stimulation of the left vagus nerve could
reduce seizure frequency in patients with refractory
epilepsy40–43. The E01 and E02 studies were two pilot
studies that enrolled 15 patients with refractory partial
epilepsy of whom 14 received stimulation. In one
patient the NCP device was explanted because of a
surgical complication that resulted in unilateral vocal
cord paralysis which resolved 9 months later. The
degree of response ranged from no improvement to
complete cessation of seizures with a mean reduction
of 46.6%. In none of the patients did the seizure
disorder appear to have exacerbated by VNS. Of
14 patients, five reported a reduction in seizure
frequency of at least 50%. None of the patients
reported transient or permanent serious side effects.
The most common side effects were noted only
during actual stimulation of the nerve and consisted
of hoarseness and local neck/throat paraesthesias.
These effects became milder after a few months of
stimulation. No cardiac or gastrointestinal negative
effects were observed on ECG monitoring and
measurements of gastric acid output.
The E03 (114 patients) and E05 (196 patients)
studies were both randomized, blinded, active control
trials in which patients with refractory partial epilepsy
were randomly assigned into two treatment groups.
Patients assigned to treatment with ‘high’ stimulation
parameters (output current: 0.25–3 mA; frequency:
20–50 Hz; pulse width: 500 µseconds; on-time: 30–
90 seconds; off- time: 5–10 minutes) were believed
to receive therapeutic treatment. Treatment with ‘low’
stimulation parameters (output current: 0.25–2.75
mA; frequency: 1– 2 Hz; pulse width: 130 µseconds;
on-time: 30 seconds; off-time: 60–180 minutes) was
considered to be non-therapeutic. The primary efficacy
endpoint was the percentage reduction in seizure
rate measured over a period of 12 weeks. Adverse
events were assessed at each patient visit. In the high
stimulation groups there was a mean reduction in
seizure frequency of 24 and 28% in the E03 and E05
studies, respectively. This is a statistically significant
decrease in seizure frequency when compared with
baseline seizure frequency and seizure frequency
reduction in the low stimulation groups (6 and 15%,
respectively). The most common treatment related
adverse events were attributable to vagal innervation
of the larynx during current ‘on’ periods and consisted
of voice alteration, coughing, throat paraesthesias and
discomfort and dyspnea. Treatment was well tolerated;
97% of patients remained in the long-term follow-
up phase of the study. Surgical-related complications
included left vocal cord paralysis in two patients,
lower facial muscle paresis in two patients, fluid
accumulation over the generator requiring aspiration
in one patient. All these complications resolved.
Infection around the device occurred in three patients.
VNS had no effect on concurrent AED serum levels
or on body chemistry. Rigorous blinded collection
of autonomic measures revealed no effect on weight,
serum gastrin, cardiac or pulmonary function tests.
Administered at levels that do not exceed comfort
electrical stimulation of the left vagus nerve has no
demonstrable effects on visceral functions. The E04
study was an open study in which 116 patients with all
types of epilepsy and patients under 12 years of age
were stimulated. In this study 29% of the implanted
patients had a seizure reduction of more than 50%.
Long-term efficacy and safety
Long-term data (>3 months) were collected on
all available E01–E04 study patients. These long-
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Table 1: Stimulation parameters available with the NCPTM system.
Parameter Units Range Typical parameter value
Output current Milliamperes (mA) 0–3.5 mA 1.25 mA
Signal frequency Hertz (Hz) 1–143 Hz 30 Hz
Pulse width Microseconds (µs) 130–1000 µs 500 µs
Signal on-time Seconds (s) 7 s (rapid cycle)–270 s 30
Signal off-time Seconds–minutes (s, min) 14 s (rapid cycle)–180 min 5 min
Lead impedance Kiloohms (Kohms) <1–7 Kohms 3–4 Kohms
term follow-up data are uncontrolled because they
come from an open-label protocol in which both
the AED medications and NCP device settings were
allowed to be changed. Patients initially randomized
to low stimulation parameters were changed to high
stimulation parameters. George et al.44 reported
18-months efficacy analysis in 50 patients exiting
the E03 study and Salinsky et al.45 reported efficacy
data in 100 of 114 patients from the E03 study that
were treated for 1 year. Results indicated that VNS
remains as effective over time and a trend towards
improved seizure control with longer use of VNS
was observed. Response during the first 3 months of
treatment is predictive of long-term response. Chronic
side effects were identical to those observed during
the randomized trials and consisted mainly of mild
hoarseness during stimulus delivery. Several other
reports on long-term treatment with VNS confirm
these findings46, 47. In our own study47 up to 10%
of patients became seizure free. Ben-Menachem48
recently published data on 64 patients with follow-
up of up to 5 years. The study included patients with
partial seizures, Lennox–Gastaut syndrome (LGS)
and primary generalized seizures (PGS). Forty-four
percent of patients experienced a large reduction in
seizure frequency and severity over long periods of
time. VNS seems equally efficacious for LGS and PGS
but results from larger patient groups are necessary.
Two patients became pregnant and have given birth to
healthy babies.
Bradycardia and asystole have been reported as a
rare complication during intraoperative testing of the
NCPTM device, probably due to stimulation of the
cervical cardiac branches of the vagus nerve either
directly or by collateral current spread49. Patients
treated with VNS have a comparable rate of sudden
unexpected unexplained death (SUDEP) compared
to patients treated with novel antiepileptic drugs.
The SUDEP rate became lower during a 2-year
follow-up50.
Little is known about the cognitive effects of
VNS. All studies agree that VNS lacks the some-
times considerable cognitive side effects of many
antiepileptic drugs. Measures of neuropsychological
outcome in different patient populations showed a
moderate improvement in mental functioning, mood
and behaviour51–53. Specific enhancement of recog-
nition memory was demonstrated following VNS by
Clark et al.54.
VNS is currently being investigated for use in major
depression. The first human trials showed significant
improvements of several mood scores during short-
time follow-up55, 56. VNS has also been shown to
suppress experimentally induced pain by a central
inhibitory effect57.
Experience in children and elderly
Experience with VNS in children is less extensive
than in adults but results seem promising. Two studies
report seizure frequency reductions of >60% in 80%
of children and >50% in 38% of children58. The most
recent and largest study in 60 children with mean age
of 15 years reported a reduction in seizure frequency
similar to that in adults59. Median reduction of seizure
frequency was 44%. A gradual increase in efficacy
up to 18 months post-operatively was observed. The
predominant seizure type in this study was complex
partial (57%) followed by generalized tonic–clonic
seizures (27%). No particular seizure or epilepsy type
appeared particularly sensitive or resistant to VNS.
Adverse events during stimulation included fever,
coughing, colds and voice alteration. No patients
dropped out and side effects subsided over time.
A single review of 45 patients older than 50, who
participated in the E03, E04 and E05 trials, showed
that more than 60% of patients had a >50% seizure
reduction after a follow-up of 1 year. Side effects were
mild and transient and quality of life scores improved
significantly60.
COST–BENEFIT CONSIDERATIONS
VNS is a costly treatment. Few cost–benefit data
are available. A recent study showed that there
is a significant decrease in epilepsy related direct
medical costs after implantation with the vagus nerve
stimulator. This decrease is mainly due to an important
decrease in the number of hospital admission days
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after implantation. It is estimated that the cost of
the device can be paid back by savings in epilepsy-
related direct medical costs after 2.5 years. Battery
life now exceeds 4 years61. The current generator
model has an estimated battery life of 8 years. In a
comparative study of conservative treatment, resective
epilepsy surgery and VNS, VNS was demonstrated to
have a favourable cost-efficacy in patients who were
unsuitable candidates for resective surgery62.
CURRENT PRACTICAL MANAGEMENT
In many epilepsy centres VNS is a routinely per-
formed treatment for patients who are unsuitable
candidates for epilepsy surgery or who have had insuf-
ficient benefit from such a treatment. When patients
with refractory epilepsy are referred to our epilepsy
centre they are initially included in a pre-surgical
evaluation protocol including video-EEG monitoring,
optimum magnetic resonance imaging (MRI), PET
and neuropsychological examination. Results of these
examinations are discussed in the epilepsy surgery
meeting by a multidisciplinary team. Patients who are
considered unsuitable candidates for resective surgery
can be included in phase-III drug trials with new
AEDs or they can be offered implantation with a
vagus nerve stimulator. Absolute contraindications
for implantation of a vagus nerve stimulator are
limited to previous left or bilateral cervical vagotomy.
A stimulator will not be implanted when there is
evidence of progressive intracerebral disease. This
does not necessarily include patients with progressive
myoclonic epilepsy, tuberous sclerosis, hypothalamic
hamartoma, etc.63–65. Other conditions that need
special attention are cardiac arrhythmias, respiratory
diseases like asthma and pre-existing hoarseness,
gastric ulcers, vasovagal syncope and coexisting
neurological diseases other than epilepsy. Patients who
were evaluated for epilepsy surgery several years ago
when treatment with a vagus nerve stimulator was not
yet routinely available are rediscussed on the epilepsy
surgery meeting and will be reevaluated with current
optimum MRI or repeated pre-surgical investigations
(e.g. video-EEG monitoring) when updating of the
available clinical data set seems necessary.
Patients are extensively informed about the efficacy,
side effects, implantation procedure and ramping up
procedure. After informed consent is obtained they
are admitted into a neurosurgical unit for 48 hours.
The surgical procedure is performed under general
anaesthesia and lasts about 1 hour. Patients leave
the hospital with the stimulator unprogrammed. Two
to four weeks after the operation the vagus nerve
stimulator is programmed to continuous intermittent
stimulation during a clinic visit, starting by an initial
0.25–0.50 mA output current depending on individual
patient tolerance. Every 2–4 weeks the stimulation
output current is gradually ramped up with 0.25–
0.50 mA until clinical efficacy or patient tolerance
is reached. When patients are used to the electrical
stimulation they are provided with the magnet. At
every clinic visit seizure frequency and side effects are
assessed. AEDs remain unchanged during ramping up.
Tapering of AEDs may be considered when seizure
freedom is achieved. After ramping up patients are
seen in follow-up every 3–4 months. The presence of
the NCPTM is not considered a contraindication for
performing an MRI, provided that the generator be
turned of during the imaging sequences, that lengthy
MRI sessions be avoided and only a transmit and
receive type head coil be used. If the pulse generator
is implanted with the electrode inputs parallel to the
long axis of the body, it need not be deactivated when
an MRI scan is performed66.
CONCLUSION
VNS is an efficacious but palliative treatment for
patients with refractory epilepsy. The current con-
sensus on efficacy is that 1/3 of patients have a
considerable improvement in seizure control with a
reduction in seizure frequency of at least 50%, 1/3 of
patients experience a worthwhile reduction of seizure
frequency between 30 and 50%. In the remaining 1/3
of the patients there is little or no effect. Efficacy
has a tendency to improve with longer duration of
treatment up to 18 months post-operatively. There
is only limited information on patients becoming
seizure free. VNS seems equally efficient for children.
Analysis of larger patient groups and insight in the
mode of action may help to identify patients with
epileptic seizures or syndromes that respond better
to VNS and guide the search for optimal stimulation
parameters. Further improvement of clinical efficacy
of VNS and development of other neurostimulation
strategies for epilepsy may result from this. In the near
future, VNS is likely to be used as a treatment for other
conditions such as depression and pain.
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